Serum and tissue levels of insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 231-237

  Jozefiak, Agata ^a   Pacholska Bogalska, Joanna ^b   Myga Nowak, Magdalena ^b   Kedzia, Witold ^a   Kwasniewska, Anna ^c   Luczak, Michal ^a   Kedzia, Helena ^a   Gozdzicka Jozefiak, Anna ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cervical cancer; Human papillomavirus; Insulin like growth factor I

Indexed keywords

HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; AUTOCRINE EFFECT; BLOOD LEVEL; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEAR LOCALIZATION SIGNAL; PARACRINE SIGNALING; TISSUE LEVEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 69249086635     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
2. Rotwein P, Pollock KM, Didier DK and Krivi GG: Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem 15: 4828-4832, 1986. (Pubitemid 17204268)
3. Kamai Y, Mikawa S, Endo K, Sakai H and Komano T: Regulation of insulin-like growth factor-I expression in mouse preadipocyte Ob1771. J Biol Chem 271: 9883-9886, 1996. (Pubitemid 26131538)
4. Shavlakadze, Winn N, Rosenthal N and Grounds MD: Reconciling data from transgenic mice that overexpress IGF-1 specifically in skeletal muscle. Growth Horm IGF Res 15: 4-18, 2005. (Pubitemid 40220850)
5. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
6. LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163, 1995.
7. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998. (Pubitemid 28067285)
8. Yu H, Spitz MR, Mistry J, Gu J, Hong WK and Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156, 1999. (Pubitemid 29042692)
9. Wu X, Yu H, Amos CI, Hong WK and Spitz MR: Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92: 737-743, 2000. (Pubitemid 30365534)
10. Hankinson SE, Wilett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998. (Pubitemid 28209997)
11. Kaaks R, Toniolo P, Akhmedkhanov A, et al: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92: 1592-1600, 2000. (Pubitemid 30770509)
12. Pollak M: Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-1228, 2000. (Pubitemid 30407009)
13. Wu X, Zhao H, Do KA, Johnson MM, Dong Q, Hong WK and Spitz MR: Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 10: 3988-3995, 2004. (Pubitemid 38812472)
14. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR and Follen M: Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 9: 3356-3361, 2003. (Pubitemid 37082730)
15. Serrano ML, Romero A, Cendales R, Sanchez-Gomez M and Bravo MM: Serum levels of insulin-like growth factor-I and II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica 26: 258-268, 2006.
16. Goldie SJ: Health economy and cervical cancer prevention: a global perspective. Virus Res 89: 301-309, 2002.
17. Wang L, Ma W, Markovich R, Lee WL and Wang PH: Insulinlike growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 139: 1354-1360, 1998. (Pubitemid 28510157)
18. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 29: 1472-1481, 2000.
19. Ayabe T, Tsutsumi O, Sahai H, Yoshikawa H, Yano T, Kurimoto F and Taketani Y: Increased circulating levels of insulin-like growth factor bindings protein in postmenopausal women with endometrial cancer. Endocr J 44: 419-424, 1997.
20. Barton ER: The ABC soft IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab 31: 791-797, 2006.
21. Ohtsuki T, Otsuki M, Murakami Y, et al: Organ-specific and age-dependent expression of insulin-like growth factor-I (IGF-I) mRNA variants: IGF-IA and IGF-IB mRNAs in the mouse. Zoolog Sci 22: 1011-1021, 2005. (Pubitemid 41566290)
22. Ekman-Ordeberg G, Stjernholm Y, Wang H, Stygar D and Sahlin L: Endocrine regulation of cervical ripening in humans - potential role for gonadal steroids and insulin-like growth factor-I. Steroids 68: 837-847, 2003. (Pubitemid 37532408)
23. Smith PJ, Spurrell EL, Coakley J, Hinds CJ, Ross RJ, Krainer AR and Chew SL: An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor2/alternative splicing factor. Endocrinology 143: 146-154, 2007. (Pubitemid 34056413)
24. Tan DS, Cook A and Chew SL: Nucleolar localization of an isoform of the IGF-I precursor. BMC Cell Biol 3: 17, 2002. (Pubitemid 38597743)
25. McPhillips MG, Veerapraditsin T, Cumming SA, et al: SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J Virol 78: 10598-10605, 2004. (Pubitemid 39258386)
26. Ham J, Dostatni N, Gauthier JM and Yaniv M: The papillomavirus E2 protein: a factor with many talents. Trends Biochem Sci 16: 440-444, 1991. (Pubitemid 121004490)
27. Doorbar J: The papillomavirus life cycle. J Clin Virol 32 (Suppl. 1): S7-S15, 2005.
28. Huibregtse JM, Scheffner M and Howley PM: Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13: 775-784, 1993. (Pubitemid 23040242)
29. Jewers RJ, Hildebrandt P, Ludow JW, Kell B and McCance DJ: Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66: 1329-1335, 1992.
30. Baege AC, Disbrow GL and Schlegel R: IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-I-induced mitogenesis. J Virol 78: 5720-5727, 2004.
31. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P and Zwerschke W: Human papillomavirus type 16E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol 20: 6483-6495, 2000. (Pubitemid 30650235)
32. Berger AJ, Baege A, Guillemette T, et al: Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol 161: 603-610, 2002. (Pubitemid 36142168)
33. Tavassoli FA and Deville P (eds): IARC Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, 2003.